Merrimack (MACK) Q3 Loss Narrower than Expected, Stock Up Thu, 09 Nov 2017 14:45:02 +0000 Merrimack (MACK) reported narrower-than-expected loss in the third quarter. With no marketed product after Onivyde sale, the company is now focused on developing its pipeline candidates.
Adaptimmune Therapeutics Plc :ADAP-US: Earnings Analysis: Q3, 2017 By the Numbers : November 8, 2017 Wed, 08 Nov 2017 19:40:11 +0000 Categories: Yahoo FinanceGet free summary analysis Adaptimmune Therapeutics Plc reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of Adaptimmune Therapeutics Plc – Affimed N.V. and Axovant Sciences Ltd (AFMD-US and AXON-US) that have also reported for this period. Highlights Summary numbers: Revenues of USD 28.23 million, ... Read more
(Read more...)
Adaptimmune marks Official Opening of U.K. Headquarters Mon, 06 Nov 2017 13:09:21 +0000 PHILADELPHIA and OXFORD, U.K., Nov. 06, 2017-- Adaptimmune Therapeutics plc, a leader in T-cell therapy to treat cancer, today announced that it will host an official opening ceremony at its new U.K. headquarters ...
*Winners defined as our Top Picks that increased 20% or more within a 6-month period.
Red Letters imply that that particular criteria did not meet minimum requirements, e.g., a low GSA Rank would show it in red.
___ Red Line On Graph Shows a Trailing Stop Loss Based on Support and Resistance Levels. See how it works.
___ Blue Line On Graph Shows the 10-Week Moving Average.
___ Magenta Line On Graph Shows the 40-Week Moving Average.
Disclaimer The stock selections in our stock investing and stock trading database are not stock recommendations, but simply represent applications of a stock investing process. All materials, including our Top Stock Picks, are provided for information purposes only and should not be used or construed as an offer to sell, a solicitation of an offer to buy, or a recommendation for any security. Growth Stock Analytics, LLC is not responsible for gains/losses that may result in investing or trading in these securities. All information is believed to be obtained from reliable sources, but there is no guarantee that the information supplied is accurate, complete or timely. There is no guarantee or warranty with regard to the results obtained from its use. There is no guarantee of suitability or potential value of any particular investment or information source. You acknowledge that your requests for this information are unsolicited and shall neither constitute nor be considered investment advice. Past investing performance is not an indication of future performance results. Investing and trading in stocks is risky. Investors are encouraged to consult a registered stock broker or investment adviser before making any investing decisions. The interpretations and opinions expressed herein are solely those of Growth Stock Analytics, LLC, and not of any other individual or organization.